• English 
    • español
    • English
    • français
  • FacebookPinterestTwitter
  • español
  • English
  • français
View Item 
  •   DIGIBUG Home
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • View Item
  •   DIGIBUG Home
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A P(V) platform for oligonucleotide synthesis

[PDF] Articulo principal (2.331Mb)
Identificadores
URI: https://hdl.handle.net/10481/101157
DOI: 10.1126/science.abi9727
Exportar
RISRefworksMendeleyBibtex
Estadísticas
View Usage Statistics
Metadata
Show full item record
Author
Huang, Yazhong; Knouse, Kyle W.; Qiu, Shenjie; Hao, Wei; Vantourout, Julien C.; Zheng, Bin; Mercer, Stephen E.; Lopez-Ogalla, Javier; Narayan, Rohan; Olson, Richard E.; Blackmond, Donna G.; Eastgate, Martin D.; Schmidt, Michael A.; McDonald, Ivar M.; Baran, Phil S.; Muñoz Padial, Natalia
Editorial
American Association for the Advancement of Science: AAAS, USA.
Date
2021-09-10
Referencia bibliográfica
Science, 2021, 373, 1265–1270
Sponsorship
We thank D.-H. Huang and L. Pasternack (Scripps Research) for assistance with NMR spectroscopy; J. Chen (Automated Synthesis Facility, Scripps Research) for purification of compounds and acquisition of HRMS data; A. L. Rheingold, C. E. Moore, and M. Gembicky (UCSD) for x-ray analysis; and S. Mukherjee (BMS) for calculating the process mass intensity. Funding: This work was supported by Bristol Myers Squibb, NIGMS (GM106210), NIH (grant number GM-118176), Marie Skłodowska-Curie Global Fellowships (749359-EnanSET, N.M.P) within the European Union research and innovation framework program (2014-2020), and the NSF SURF Program (TSRI, R.N).
Abstract
The promise of gene-based therapies is being realized at an accelerated pace, with more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides, by far most of which contain modified phosphate linkages. These unnatural linkages have desirable biological and physical properties but are often accessed with difficulty using phosphoramidite chemistry. We report a flexible and efficient [P(V)]–based platform that can install a wide variety of phosphate linkages at will into oligonucleotides. This approach uses readily accessible reagents and can install not only stereodefined or racemic thiophosphates but any combination of (S, R or rac)–PS with native phosphodiester (PO2) and phosphorodithioate (PS2) linkages into DNA and other modified nucleotide polymers. This platform easily accesses this diversity under a standardized coupling protocol with sustainably prepared, stable P(V) reagents.
Collections
  • FQM339 - Artículos

My Account

LoginRegister

Browse

All of DIGIBUGCommunities and CollectionsBy Issue DateAuthorsTitlesSubjectFinanciaciónAuthor profilesThis CollectionBy Issue DateAuthorsTitlesSubjectFinanciación

Statistics

View Usage Statistics

Servicios

Pasos para autoarchivoAyudaLicencias Creative CommonsSHERPA/RoMEODulcinea Biblioteca UniversitariaNos puedes encontrar a través deCondiciones legales

Contact Us | Send Feedback